Tags Archive Navigation
icon
-
Media ReleaseSandoz announces positive results from Mylight Phase lll study for biosimilar aflibercept
-
Media ReleaseNovartis signs agreement to divest ‘front of eye’ ophthalmology assets in line with focused strategy
-
Media ReleaseNovartis announces European Commission approval of Beovu® for people living with diabetic macular edema
-
Media ReleaseNovartis to acquire Gyroscope Therapeutics, adding a one-time gene therapy that could transform care for geographic atrophy, a leading cause of blindness
-
Media ReleaseNovartis announces FDA and EMA filing acceptances of Beovu® for patients with diabetic macular edema
-
Media ReleaseNovartis announces positive results from Phase III trials of Beovu® in diabetic macular edema, including dosing intervals up to 16 weeks
-
Media ReleaseNovartis übernimmt Arctos Medical und erweitert damit ihr Optogenetik-Portfolio, um Patientinnen und Patienten mit einem schwerem Verlust des Sehvermögens Gentherapien anbieten zu können
-
Media ReleaseNovartis acquiert Arctos Medical, élargissant ainsi son portefeuille d’optogénétique afin de proposer des thérapies géniques aux patients souffrant d’une sévère perte de la vision
-
Media ReleaseNovartis acquires Arctos Medical, expanding optogenetics portfolio to bring gene therapies to patients with severe vision loss
-
Media ReleaseNovartis reports positive topline results from the first Phase III trial of Beovu® versus aflibercept in patients with diabetic macular edema (DME)
-
Media ReleaseEuropean Medicines Agency (EMA) approves safety label update for Novartis Beovu®
-
Media ReleaseNew Phase III analysis demonstrates Novartis Beovu® showed improvement in best-corrected visual acuity in wet AMD patients with early persistent fluid